Ottobock adds WIM S walking robot to US consumer offering
Germany’s Ottobock will distribute WIRobotics’ wearable walking-assist robot in the United States, combining online sales with try-ons at selected clinics.

Germany’s Ottobock will sell South Korean company WIRobotics’ WIM S walking-assist robot in the United States as a wellness device, pairing online distribution with opportunities to try it at selected orthotic and prosthetic clinics. No price has been announced.
The distribution and sales agreement, announced on November 16, 2026, was signed on October 15 between WIRobotics USA Inc. and Otto Bock HealthCare LP. It covers the United States and Canada, but sales through the partnership will begin in the US. A Canadian rollout will be considered based on customer feedback.
For Ottobock, the agreement extends an existing North American business rather than marking a first entry into the market. The German mobility specialist is putting its distribution, clinical-care and service networks behind a consumer wearable made by an external robotics supplier.
Online sales, with a physical trial channel
Consumers will be able to purchase WIM S through Ottobock’s dedicated direct-to-consumer online platform and WIRobotics USA’s online store. Selected orthotic and prosthetic clinics will initially offer hands-on trials, with additional US locations under consideration as the companies assess demand.
That combination gives the launch a physical demonstration channel alongside online purchasing. For a product worn on the body to assist movement, the opportunity to try it is a distinct part of the sales proposition. The announcement does not identify the participating clinics or specify how many will offer demonstrations.
The partners also plan to collaborate on market development, brand building, product training and after-sales service. WIRobotics USA will support training and service locally, adding an operational support layer to the distribution agreement.
Wellness positioning—not medical clearance
WIM S is worn around the hips and secured with waist and thigh straps. According to Securities.io’s account of WIRobotics USA’s product information, it weighs 3.5 pounds including its battery and worn components. Bluetooth connectivity allows users to choose modes, adjust assistance and view gait scores and progress.
Its modes include assistance for ordinary walking, resistance for activity, support for shorter and slower strides, and help on slopes and stairs. These features position the product around everyday movement and exercise rather than a single clinical application.
The distinction matters because clinic demonstrations do not make WIM S a medical product. Securities.io reports that WIRobotics USA explicitly classifies it as a wellness activity device, with no FDA clearance and no medical claims. The initial US offering should therefore be distinguished from a regulated rehabilitation-device launch.
An established German platform for a new offering
Founded in Berlin in 1919, Ottobock works across prosthetics, neuro-orthotics and exoskeletons. The partnership announcement describes a business active in 45 countries, employing nearly 9,300 full-time equivalents and operating more than 430 patient-care clinics worldwide. Those are global figures, not the footprint of the WIM S launch.
The strategic value lies in using that established mobility infrastructure to introduce another consumer-facing technology. Ottobock contributes access and support capabilities; WIRobotics supplies the robot. The arrangement broadens Ottobock’s offering without representing an acquisition of the developer.
A medical extension remains possible but separate. The companies are exploring cooperation on WIM Medi, which WIRobotics is developing for medical use. Entry into US and Canadian medical and rehabilitation channels would require applicable regulatory authorization and another agreement.
For now, the commercial test is narrower: whether online access, clinic trials and local service can build US demand for WIM S as a wellness product. Pricing, the initial clinic footprint and customer response will be important measures of that rollout.

![Illustration for: Agile Robots Raises $500M at $8.5B, SoftBank Leads [2026]](/api/public/media/1794808862946-autopilot-agile-robots-500m-funding-us-expansion-uia1.png)
